Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 27, 2025
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
GlobeNewswire
·
May 27, 2025
REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. (“STORM”) to evaluate STC-15, a METTL3 inhibitor, in combination with …
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis
GlobeNewswire
·
May 27, 2025
Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK) No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed across SAD/MAD cohorts Management releases a “ …
Strongline returns to market, signs deal with QLog to ensure leading staff duress offering is available to health systems around the country
GlobeNewswire
·
May 27, 2025
SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- Commure announced today a strategic partnership and licensing agreement with QLog, a leading Israeli innovator in real-time location systems (RTLS) and Bluetooth Low Energy (BLE) technologies for healthcare. …
BioNTech präsentiert auf der ASCO-Jahrestagung 2025 Fortschritte aus der diversifizierten Onkologie-Pipeline
GlobeNewswire
·
May 27, 2025
MAINZ, Deutschland, 27. Mai 2025 -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der Jahrestagung der American Society of Clinical Oncology („ASCO“), die vom 30. Mai bis 3. Juni 2025 in Chicago, Illinois, stattfindet, klinische …
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
GlobeNewswire
·
May 27, 2025
MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company’s diversified oncology portfolio at the American Society of Clinical Oncology (“ASCO …
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
GlobeNewswire
·
May 27, 2025
NEEDHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025
GlobeNewswire
·
May 27, 2025
Presentation at ESMO will follow oral 2025 ASCO Annual Meeting presentation highlighting unprecedented survival data from Phase 2 OVATION 2 Study of IMNN-001 Simultaneously publication in leading peer-reviewed journal Gynecologic Oncology details IMNN-001’ …
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire
·
May 27, 2025
DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop …
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
GlobeNewswire
·
May 27, 2025
EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery …
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 27, 2025
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to …
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Completion of Enrollment of the Global Phase 2b Study Evaluating Naronapride in Gastroparesis (MOVE-IT)
GlobeNewswire
·
May 27, 2025
ROSCREA, Ireland and FREIBURG, Germany, May 27, 2025 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) …
Avalyn Announces Upcoming Presentation on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the European Congress of Rheumatology 2025
GlobeNewswire
·
May 27, 2025
CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced an upcoming presentation at the …
MIMEDX to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 27, 2025
MARIETTA, Ga., May 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 22nd Annual …
Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for FLT201, its Clinical-Stage Gene Therapy Candidate in Gaucher Disease
GlobeNewswire
·
May 27, 2025
LONDON, May 27, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced the publication of preclinical proof-of-concept data for FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease in Molecular Therapy, the flagship …
Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
May 27, 2025
SEATTLE, May 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the …
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
GlobeNewswire
·
May 27, 2025
CARMEL, Ind., May 27, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults …
Merus to Present at Upcoming Investor Conferences
GlobeNewswire
·
May 27, 2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics …
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
GlobeNewswire
·
May 27, 2025
NAARDEN, the Netherlands and MIAMI, May 27, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at …
Emory Healthcare Researchers Use Dynamic Digital Radiography to Compare Shoulder Improvement of Two Surgical Interventions for Massive Irreparable Rotator Cuff Tears
GlobeNewswire
·
May 27, 2025
WAYNE, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc., congratulates Emory Healthcare researchers on the publication of a new study using Dynamic Digital Radiography (DDR) to compare shoulder biomechanics in patients after …
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
GlobeNewswire
·
May 27, 2025
- Study will assess relative efficacy, safety, and immunogenicity of Vaxart’s oral pill COVID-19 vaccine candidate against an approved mRNA comparator at 12 months - SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) …